- Home
- CRGX vs MAX Comparison
CRGX vs MAX Comparison
Compare CRGX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- MAX
- Stock Information
- Founded
- CRGX 2021
- MAX 2014
- Country
- CRGX United States
- MAX United States
- Employees
- CRGX N/A
- MAX N/A
- Industry
- CRGX
- MAX Industrial Machinery/Components
- Sector
- CRGX
- MAX Industrials
- Exchange
- CRGX Nasdaq
- MAX Nasdaq
- Market Cap
- CRGX 190.0M
- MAX 582.4M
- IPO Year
- CRGX 2023
- MAX 2020
- Fundamental
- Price
- CRGX $4.46
- MAX $10.50
- Analyst Decision
- CRGX Hold
- MAX Strong Buy
- Analyst Count
- CRGX 7
- MAX 6
- Target Price
- CRGX $4.67
- MAX $17.92
- AVG Volume (30 Days)
- CRGX 502.9K
- MAX 418.7K
- Earning Date
- CRGX 08-11-2025
- MAX 07-30-2025
- Dividend Yield
- CRGX N/A
- MAX N/A
- EPS Growth
- CRGX N/A
- MAX N/A
- EPS
- CRGX N/A
- MAX 0.28
- Revenue
- CRGX N/A
- MAX $1,002,364,000.00
- Revenue This Year
- CRGX $57.81
- MAX $24.09
- Revenue Next Year
- CRGX N/A
- MAX $11.18
- P/E Ratio
- CRGX N/A
- MAX $37.89
- Revenue Growth
- CRGX N/A
- MAX 148.62
- 52 Week Low
- CRGX $3.00
- MAX $7.33
- 52 Week High
- CRGX $25.45
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- CRGX 57.89
- MAX 47.90
- Support Level
- CRGX $4.09
- MAX $10.39
- Resistance Level
- CRGX $4.51
- MAX $11.19
- Average True Range (ATR)
- CRGX 0.18
- MAX 0.35
- MACD
- CRGX 0.00
- MAX -0.08
- Stochastic Oscillator
- CRGX 77.18
- MAX 15.95
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.